Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: Importance of MyD88

Journal of Immunology

Volumn 189, Issue 9, 2012, Pages 4496-4509

  Zhang, Xiuli ^a,c   Dervillez, Xavier ^a   Chentoufi, Aziz Alami ^a,d   Badakhshan, Tina ^a   Bettahi, Ilham ^a,e   BenMohamed, Lbachir ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KING FAHAD MEDICAL CITY   (Saudi Arabia)

^e WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; HERPES VACCINE; INTERLEUKIN 2; LIPOPEPTIDE VACCINE; MYELOID DIFFERENTIATION FACTOR 88; PROGESTERONE; RECOMBINANT ADENOVIRUS 5 VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG TARGETING; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL GANGLION; VAGINA MUCOSA; VIRUS REPLICATION;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENITALIA, FEMALE; HERPES GENITALIS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; LIPOPEPTIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOUS MEMBRANE; MYELOID DIFFERENTIATION FACTOR 88; VACCINES, ADENOVIRUS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84867907515     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201121     Document Type: Article

References (58)

1. Chentoufi, A. A., E. Kritzer, D. M. Yu, A. B. Nesburn, and L. Benmohamed. 2012. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Clin. Dev. Immunol. 2012: 187585.
2. Mestecky, J., M. W. Russell, and C. O. Elson. 2007. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J. Immunol. 179: 5633-5638.
3. Belyakov, I. M., and J. D. Ahlers. 2009. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183: 6883-6892.
4. Iwasaki, A. 2010. Antiviral immune responses in the genital tract: clues for vaccines. Nat. Rev. Immunol. 10: 699-711.
5. King, N. J., E. L. Parr, and M. B. Parr. 1998. Migration of lymphoid cells from vaginal epithelium to iliac lymph nodes in relation to vaginal infection by herpes simplex virus type 2. J. Immunol. 160: 1173-1180. (Pubitemid 28093412)
6. Zhang, X., A. A. Chentoufi, G. Dasgupta, A. B. Nesburn, M. Wu, X. Zhu, D. Carpenter, S. L. Wechsler, S. You, and L. BenMohamed. 2009. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2: 129-143.
7. Posavad, C. M., D. M. Koelle, M. F. Shaughnessy, and L. Corey. 1997. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc. Natl. Acad. Sci. USA 94: 10289-10294. (Pubitemid 27407034)
8. Barouch, D. H., J. Liu, H. Li, L. F. Maxfield, P. Abbink, D. M. Lynch, M. J. Iampietro, A. SanMiguel, M. S. Seaman, G. Ferrari, et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93.
9. Gebhardt, T.,L.M.Wakim,L.Eidsmo, P. C. Reading,W.R.Heath, andF. R. Carbone. 2009. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 10: 524-530.
10. Jiang, X., R. A. Clark, L. Liu, A. J. Wagers, R. C. Fuhlbrigge, and T. S. Kupper. 2012. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature 483: 227-231.
11. Mackay, L. K., A. T. Stock, J. Z. Ma, C. M. Jones, S. J. Kent, S. N. Mueller, W. R. Heath, F. R. Carbone, and T. Gebhardt. 2012. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc. Natl. Acad. Sci. USA 109: 7037-7042.
12. Corey, L., A. Wald, C. L. Celum, and T. C. Quinn. 2004. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir. Immune Defic. Syndr. 35: 435-445. (Pubitemid 38420652)
13. Dasgupta, G., and L. BenMohamed. 2011. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates? Vaccine 29: 5824-5836.
14. Dasgupta, G., A. A. Chentoufi, A. B. Nesburn, S. L. Wechsler, and L. BenMohamed. 2009. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev. Vaccines 8: 1023-1035.
15. Blaney, J. E., Jr., E. Nobusawa, M. A. Brehm, R. H. Bonneau, L. M. Mylin, T. M. Fu, Y. Kawaoka, and S. S. Tevethia. 1998. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J. Virol. 72: 9567-9574. (Pubitemid 28520820)
16. Rollier, C. S., A. Reyes-Sandoval, M. G. Cottingham, K. Ewer, and A. V. Hill. 2011. Viral vectors as vaccine platforms: deployment in sight. Curr. Opin. Immunol. 23: 377-382.
17. Qureshi, H., Z. M. Ma, Y. Huang, G. Hodge, M. A. Thomas, J. DiPasquale, V. DeSilva, L. Fritts, A. J. Bett, D. R. Casimiro, et al. 2012. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J. Virol. 86: 2239-2250.
18. Lu, S. 2009. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21: 346-351.
19. Lindsay, R. W., P. A. Darrah, K. M. Quinn, U. Wille-Reece, L. M. Mattei, A. Iwasaki, S. P. Kasturi, B. Pulendran, J. G. Gall, A. G. Spies, and R. A. Seder. 2010. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. J. Immunol. 185: 1513-1521.
20. Belshe, R. B., P. A. Leone, D. I. Bernstein, A. Wald, M. J. Levin, J. T. Stapleton, I. Gorfinkel, R. L. A. Morrow, M. G. Ewell, A. Stokes-Riner, et al Herpevac Trial for Women. 2012. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366: 34-43.
21. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, et al; GlaxoSmithKline Herpes Vaccine Efficacy Study Group. 2002. Glycoprotein-D- adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347: 1652-1661. (Pubitemid 35340783)
22. Cohen, J. 2010. Immunology. Painful failure of promising genital herpes vaccine. Science 330: 304.
23. Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2: 675-680. (Pubitemid 32747155)
24. Conrady, C. D., M. Zheng, K. A. Fitzgerald, C. Liu, and D. J. Carr. 2012. Resistance to HSV-1 infection in the epithelium resides with the novel innate sensor, IFI-16. Mucosal Immunol. 5: 173-183.
25. BenMohamed, L., Y. Belkaid, E. Loing, K. Brahimi, H. Gras-Masse, and P. Druilhe. 2002. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 32: 2274-2281. (Pubitemid 34965890)
26. Zhang, X., A. Issagholian, E. A. Berg, J. B. Fishman, A. B. Nesburn, and L. BenMohamed. 2005. Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J. Virol. 79: 15289-15301. (Pubitemid 43032311)
27. Berzofsky, J. A., J. D. Ahlers, M. A. Derby, C. D. Pendleton, T. Arichi, and I. M. Belyakov. 1999. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol. Rev. 170: 151-172. (Pubitemid 29490752)
28. Zhu, X., T. V. Ramos, H. Gras-Masse, B. E. Kaplan, and L. BenMohamed. 2004. Lipopeptide epitopes extended by Ne-palmitoyl lysine moiety increases uptake and maturation of dendritic cell through a Toll-like receptor 2 pathway and triggers a Th1-dependent protective immunity. Eur. J. Immunol. 34: 3102-3114. (Pubitemid 39549389)
29. Nelson, M. H., M. D. Bird, C. F. Chu, A. J. Johnson, B. M. Friedrich, W. R. Allman, and G. N. Milligan. 2011. Rapid clearance of herpes simplex virus type 2 by CD8+ T cells requires high level expression of effector T cell functions. J. Reprod. Immunol. 89: 10-17.
30. Iijima, N., M. M. Linehan, M. Zamora, D. Butkus, R. Dunn, M. R. Kehry, T. M. Laufer, and A. Iwasaki. 2008. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J. Exp. Med. 205: 3041-3052.
31. Bettahi, I., X. Zhang, R. E. Afifi, and L. BenMohamed. 2006. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by selfadjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol. 19: 220-236. (Pubitemid 44050321)
32. Parr, M. B., and E. L. Parr. 1997. Protective immunity against HSV-2 in the mouse vagina. J. Reprod. Immunol. 36: 77-92. (Pubitemid 27511460)
33. Khanna, K. M., R. H. Bonneau, P. R. Kinchington, and R. L. Hendricks. 2003. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 18: 593-603. (Pubitemid 36588577)
34. Tengvall, S., and A. M. Harandi. 2008. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice. J. Reprod. Immunol. 78: 49-57. (Pubitemid 351609116)
35. Lindqvist, M., J. Persson, K. Thörn, and A. M. Harandi. 2009. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 182: 6435-6443.
36. Davey, G. M., M. Wojtasiak, A. I. Proietto, F. R. Carbone, W. R. Heath, and S. Bedoui. 2010. Cutting edge: priming of CD8 T cell immunity to herpes simplex virus type 1 requires cognate TLR3 expression in vivo. J. Immunol. 184: 2243-2246.
37. Nakanishi, Y., B. Lu, C. Gerard, and A. Iwasaki. 2009. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462: 510-513.
38. Bolton, D. L., K. Song, R. L. Wilson, P. A. Kozlowski, G. D. Tomaras, B. F. Keele, R. V. Lovingood, S. Rao, and M. Roederer. 2012. Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge. Mucosal Immunol. 5: 41-52.
39. Wilks, A. B., E. C. Christian, M. S. Seaman, P. Sircar, A. Carville, C. E. Gomez, M. Esteban, G. Pantaleo, D. H. Barouch, N. L. Letvin, and S. R. Permar. 2010. Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J. Immunol. 185: 7097-7106.
40. Dervillez, X., C. Gottimukkala, K. W. Kabbara, C. Nguyen, T. Badakhshan, S. M. Kim, A. B. Nesburn, S. L. Wechsler, and L. Benmohamed. 2012. Future of an "asymptomatic" T-cell epitope-based therapeutic herpes simplex vaccine. Future Virol. 7: 371-378.
41. Dasgupta, G., A. A. Chentoufi, M. Kalantari, P. Falatoonzadeh, S. Chun, C. H. Lim, P. L. Felgner, D. H. Davies, and L. BenMohamed. 2012. Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals. J. Virol. 86: 4358-4369.
42. Zhao, X., E. Deak, K. Soderberg, M. Linehan, D. Spezzano, J. Zhu, D. M. Knipe, and A. Iwasaki. 2003. Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J. Exp. Med. 197: 153-162. (Pubitemid 36152310)
43. Gebhardt, T., P. G. Whitney, A. Zaid, L. K. Mackay, A. G. Brooks, W. R. Heath, F. R. Carbone, and S. N. Mueller. 2011. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature 477: 216-219.
44. Chentoufi, A. A., and L. BenMohamed. 2010. Future viral vectors for the delivery of asymptomatic herpes epitope-based immunotherapeutic vaccines. Future Virol. 5: 525-528.
45. Chentoufi, A. A., N. R. Binder, N. Berka, G. Durand, A. Nguyen, I. Bettahi, B. Maillère, and L. BenMohamed. 2008. Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J. Virol. 82: 11792-11802.
46. Zhu, J., D. M. Koelle, J. Cao, J. Vazquez, M. L. Huang, F. Hladik, A. Wald, and L. Corey. 2007. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 204: 595-603. (Pubitemid 46457082)
47. Milligan, G. N., and D. I. Bernstein. 1997. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 229: 259-268. (Pubitemid 27243509)
48. Chan, T., N. G. Barra, A. J. Lee, and A. A. Ashkar. 2011. Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa. J. Reprod. Immunol. 88: 210-218.
49. Bird, M. D., C. F. Chu, A. J. Johnson, and G. N. Milligan. 2007. Early resolution of herpes simplex virus type 2 infection of the murine genital tract involves stimulation of genital parenchymal cells by gamma interferon. J. Virol. 81: 423-426. (Pubitemid 44975182)
50. Parr, M. B., and E. L. Parr. 1999. The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice. Virology 258: 282-294. (Pubitemid 29390237)
51. Kaufman, D. R., M. Bivas-Benita, N. L. Simmons, D. Miller, and D. H. Barouch. 2010. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J. Virol. 84: 5986-5996.
52. Bettahi, I., A. B. Nesburn, S. Yoon, X. Zhang, A. Mohebbi, V. Sue, A. Vanderberg, S. L. Wechsler, and L. BenMohamed. 2007. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest. Ophthalmol. Vis. Sci. 48: 4643-4653. (Pubitemid 351260982)
53. Chentoufi, A. A., G. Dasgupta, A. B. Nesburn, I. Bettahi, N. R. Binder, Z. S. Choudhury, W. D. Chamberlain, S. L. Wechsler, and L. BenMohamed. 2010. Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization. Clin. Vaccine Immunol. 17: 342-353.
54. Del Campo, J., M. Lindqvist, M. Cuello, M. Bäckström, O. Cabrerra, J. Persson, O. Perez, and A. M. Harandi. 2010. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine 28: 1193-1200.
55. Barouch, D. H., S. V. Kik, G. J. Weverling, R. Dilan, S. L. King, L. F. Maxfield, S. Clark, D. Ng'ang'a, K. L. Brandariz, P. Abbink, et al. 2011. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29: 5203-5209.
56. Khodai, T., D. Chappell, C. Christy, P. Cockle, J. Eyles, D. Hammond, K. Gore, M. J. McCluskie, D. M. Evans, S. Lang, et al. 2011. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin. Vaccine Immunol. 18: 1702-1709.
57. Chentoufi, A. A., X. Zhang, K. Lamberth, G. Dasgupta, I. Bettahi, A. Nguyen, M. Wu, X. Zhu, A. Mohebbi, S. Buus, et al. 2008. HLA-A*0201- restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J. Immunol. 180: 426-437.
58. Mestecky, J., and P. N. Fultz. 1999. Mucosal immune system of the human genital tract. J. Infect. Dis. 179(Suppl 3): S470-S474. (Pubitemid 29198401)